Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/22470

Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Systemic-onset juvenile idiopathic arthritis (SOJIA), formerly called Still’s disease, is a subset of juvenile arthritis that describes patients with fever, rash, arthritis, serositis and visceromegaly. In up to 30% of cases the disease has a chronic course and management requires high doses of glucocorticoids, disease-modifying antirheumatic drugs (DMARD), tumour necrosis factor alpha (TNFα) inhibitors or anakinra.1–6 However, this therapeutic arsenal is unable to control the disease in all patients.#N##N#Recently, rituximab, a chimeric anti-CD20 monoclonal antibody, has been successfully used in two patients with refractory adult-onset Still’s disease.7 As the similarity of clinical and laboratory features present in SOJIA and adult-onset Still’s disease implies that these conditions have similar …

Matèries (anglès)

Citació

Citació

NARVÁEZ GARCÍA, Francisco Javier, et al. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Annals of the Rheumatic Diseases. 2009. Vol. 68, num. 4, pags. 607-608. ISSN 0003-4967. [consulted: 19 of August of 2026]. Available at: https://hdl.handle.net/2445/22470

Exportar metadades

JSON - METS

Compartir registre